Cargando…

Changes in 12-month outcomes over time for age-related macular degeneration, diabetic macular oedema and retinal vein occlusion

OBJECTIVES: To identify whether the outcomes of neovascular age-related macular degeneration (nAMD), diabetic macular oedema (DMO) and retinal vein occlusion (RVO) in routine clinical practice have changed over time. METHODS: We analysed 12-month outcomes in treatment-naïve eyes that started afliber...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bhandari, Sanjeeb, Nguyen, Vuong, Hunt, Adrian, Gabrielle, Pierre-Henry, Viola, Francesco, Mehta, Hemal, Manning, Les, Squirrell, David, Arnold, Jennifer, McAllister, Ian L., Barthelmes, Daniel, Gillies, Mark
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9066999/ https://www.ncbi.nlm.nih.gov/pubmed/35508721 http://dx.doi.org/10.1038/s41433-022-02075-6

Ejemplares similares

12‐month outcomes of ranibizumab versus aflibercept for macular oedema in central retinal vein occlusion: data from the FRB! registry
por: Niedzwiecki, Mateusz, et al.
Publicado: (2021)

A systematic review of real-world evidence of the management of macular oedema secondary to branch retinal vein occlusion
por: Ang, Juan Lyn, et al.
Publicado: (2020)

Initial observation or treatment for diabetic macular oedema with good visual acuity: two‐year outcomes comparison in routine clinical practice: data from the Fight Retinal Blindness! Registry
por: Gabrielle, Pierre‐Henry, et al.
Publicado: (2020)

Dexamethasone Implant for Diabetic Macular Oedema: 1-Year Treatment Outcomes from the Fight Retinal Blindness! Registry
por: Bhandari, Sanjeeb, et al.
Publicado: (2022)

Three-Year Outcomes of Neovascular Age-Related Macular Degeneration in Eyes That Do Not Develop Macular Atrophy or Subretinal Fibrosis
por: Gabrielle, Pierre-Henry, et al.
Publicado: (2021)

Perifoveal Microcirculation in Macular Oedema with Retinal Vein Occlusion
por: Noma, Hidetaka, et al.
Publicado: (2012)

Five-year outcomes of eyes initially enrolled in the 2-year BEVORDEX trial of bevacizumab or dexamethasone implants for diabetic macular oedema
por: Cornish, Elisa E, et al.
Publicado: (2023)

THREE-YEAR TREATMENT OUTCOMES OF AFLIBERCEPT VERSUS RANIBIZUMAB FOR DIABETIC MACULAR EDEMA: Data from the Fight Retinal Blindness! Registry
por: Gabrielle, Pierre-Henry, et al.
Publicado: (2022)

Incidence, risk factors and outcomes of submacular haemorrhage with loss of vision in neovascular age‐related macular degeneration in daily clinical practice: data from the FRB! registry
por: Gabrielle, Pierre‐Henry, et al.
Publicado: (2022)

Hemiretinal vein occlusion 12-month outcomes are unique with vascular endothelial growth factor inhibitors: data from the Fight Retinal Blindness! Registry
por: Hunt, Adrian Robert, et al.
Publicado: (2023)

Treatments for macular oedema following central retinal vein occlusion: systematic review
por: Ford, John A, et al.
Publicado: (2014)

Indirect comparisons of ranibizumab and dexamethasone in macular oedema secondary to retinal vein occlusion
por: Thom, Howard HZ, et al.
Publicado: (2014)

Neovascular age‐related macular degeneration: A review of findings from the real‐world Fight Retinal Blindness! registry
por: Nguyen, Vuong, et al.
Publicado: (2021)

Intraocular pressure rise is predictive of vision improvement after intravitreal triamcinolone acetonide for diabetic macular oedema: a retrospective analysis of data from a randomised controlled trial
por: O’Day, Roderick F, et al.
Publicado: (2014)

Macular Oedema in Idiopathic Macular Telangiectasia Type 1 Responsive to Aflibercept but Not Bevacizumab
por: Shibeeb, O'Sam, et al.
Publicado: (2014)

Diabetic Macular Oedema Guidelines: An Australian Perspective
por: Yuen, Yew Sen, et al.
Publicado: (2023)

Comparing vision and macular thickness in neovascular age-related macular degeneration, diabetic macular oedema and retinal vein occlusion patients treated with intravitreal antivascular endothelial growth factor injections in clinical practice
por: Gurung, Rajya L, et al.
Publicado: (2021)

Baseline central macular thickness predicts the need for retreatment with intravitreal triamcinolone plus laser photocoagulation for diabetic macular edema
por: O’Day, Roderick, et al.
Publicado: (2013)

Treatment of Branch Retinal Vein Occlusion induced Macular Edema with Bevacizumab
por: Abegg, Mathias, et al.
Publicado: (2008)

Effects of switching from ranibizumab to aflibercept in eyes with exudative age-related macular degeneration
por: Barthelmes, Daniel, et al.
Publicado: (2016)

Management of Cataract in Patients with Age-Related Macular Degeneration
por: Mehta, Hemal
Publicado: (2021)

Real‐world treatment outcomes of neovascular Age‐related Macular Degeneration in the Netherlands
por: Verbraak, Frank D., et al.
Publicado: (2020)

Drug treatment of macular oedema secondary to central retinal vein occlusion: a network meta-analysis
por: Ford, John A, et al.
Publicado: (2014)

Two-year outcomes of intravitreal bevacizumab therapy for macular oedema secondary to branch retinal vein occlusion
por: Hikichi, Taiichi, et al.
Publicado: (2014)

Clinical characteristics of branch retinal vein occlusion with increased retinal haemorrhage during treatment for macular oedema
por: Lee, You Hyun, et al.
Publicado: (2020)

Efficacy and safety of widely used treatments for macular oedema secondary to retinal vein occlusion: a systematic review
por: Glanville, Julie, et al.
Publicado: (2014)

Comment on: Ranibizumab and aflibercept intravitreal injection for treatment naïve and refractory macular oedema in branch retinal vein occlusion
por: Elkazza, Sumeia A, et al.
Publicado: (2020)

Long-term outcomes for patients treated for macular oedema secondary to retinal vein occlusion: a systematic review
por: Hunter, Alexandra, et al.
Publicado: (2022)

Impact of metabolic control on macular thickness in diabetic macular oedema
por: Peng, Yi-Jie, et al.
Publicado: (2017)

Intravitreal dexamethasone implant versus triamcinolone acetonide for macular oedema of central retinal vein occlusion: quantifying efficacy and safety
por: Mishra, S. K., et al.
Publicado: (2018)

Real-World Results of Switching Treatment from Ranibizumab to Aflibercept in Macular Oedema Secondary to Branch Retinal Vein Occlusion
por: Konidaris, Vasileios E., et al.
Publicado: (2018)

Real-World Evidence for Treat-and-Extend Regimen of Ranibizumab Therapy for Macular Oedema Secondary to Branch Retinal Vein Occlusion
por: Rodríguez-Fernández, Carmen Antía, et al.
Publicado: (2022)

Short-term and long-term results after intravitreal bevacizumab therapy for macular oedema in branch retinal vein occlusion
por: Pidro, Ajla, et al.
Publicado: (2022)

Antivascular endothelial growth factor for macular oedema secondary to retinal vein occlusion: a systematic review and meta-analysis
por: Xu, Shanshan, et al.
Publicado: (2022)

Real-world outcomes of intravitreal bevacizumab treat-and-extend for cystoid macular oedema secondary to central retinal vein occlusion
por: Gildea, David, et al.
Publicado: (2023)

ASSOCIATION BETWEEN ANATOMICAL AND CLINICAL OUTCOMES OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION TREATED WITH ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR
por: Nguyen, Vuong, et al.
Publicado: (2021)

The Changes of Irisin and Inflammatory Cytokines in the Age-Related Macular Degeneration and Retinal Vein Occlusion
por: Li, Xiaochun, et al.
Publicado: (2022)

Comparative efficacy and safety of approved treatments for macular oedema secondary to branch retinal vein occlusion: a network meta-analysis
por: Regnier, Stephane A, et al.
Publicado: (2015)

Combination Therapy for Macular Oedema in Retinal Vein Occlusions: 3-Year Results from a Real-World Clinical Practice
por: Horner, Faye, et al.
Publicado: (2020)

Anti-vascular endothelial growth factor dosing frequency and visual outcomes in macular oedema following branch retinal vein occlusion
por: Modi, Yasha S., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_fpnatvf02lra854ptdnekmvp26